Pearson: Program to Bolster Patient Involvement in Review Process
The Institute for Clinical and Economic Review's (ICER) new Patient Engagement Program is a big leap forward for the drug [...]
Tufts’ Cohen Highlights ICER’s Third Value Assessment Framework
Tufts Medical Center's Joshua Cohen, deputy director of the Center for the Evaluation of Value and Risk in Health, in [...]
Analysis Looks at ICER’s FDA Outreach Plan
A recent analysis by the Pink Sheet spotlights a new initiative by the Institute for Clinical and Economic Review (ICER) [...]
ICER Plans Review of Bladder Cancer Treatment
The Institute for Clinical and Economic Review (ICER) announced plans to review FKD Therapies Oy and Ferring Pharmaceuticals' Instiladrin for [...]
Population Health with Accountable Health Founder
Fred Goldstein, president and founder of Accountable Health, chimes in on population health in the latest Relentless Health Value podcast. [...]
ICER Releases Draft Report on Cystic Fibrosis Therapies
The Institute for Clinical and Economic Review (ICER) on Thursday, Feb. 20, released a draft evidence report on treatments for [...]
Article Highlights Digital Healthcare Ecosystem
HEOR researcher and scientific writer Michele Cleary in the latest Value & Outcomes Spotlight featured article offers expert perspectives on [...]
More on Surescripts Report
A recent PatientEngagementHIT report highlights a survey by Surescripts that found high drug prices caused a little more than half [...]
Survey: More than Half of Patients Avoid Taking Medicine Due to Cost
A recent survey conducted by Surescripts, in partnership with Engine Group, suggests a little more than half of U.S. patients [...]
CMS Testing Waters with Risk-Sharing Deals with ACO Program
The Centers for Medicare and Medicaid Services (CMS) is testing risk-sharing agreements in Medicare's Direct Contracting program, according to a [...]
Blog Post: Making the Most of Our Health Care Dollars
A recent blog post on Going Below the Surface highlights a panel discussion during AcademyHealth National Health Policy Conference that [...]
Impact of Drug Pricing Controls on Innovation
The pharmaceutical industry, citing concerns over innovation, has consistently pushed back against the U.S. government's efforts to tame drug prices. [...]
3M Announces Webinar Series for Health Plans
3M this week announced a new webinar series developed specifically for health care plans. The first webinar in the series, [...]
ICER Signs Multi-Year Deal to Use New Cloud-Based Analytic Platform, hēRo3
Policy Analysis Inc. (PAI), a Boston-based health-economics consultancy, on Wednesday, Feb. 19, announced that it had signed a multi-year deal [...]
Article Reflects on NICE’s Achievements, Economic Evaluation Methods
University of York's Mark Sculpher and Stephen Palmer in a recent article published in PharmacoEconomics discuss the National Institute for [...]
Wynne Health Group’s LaRosa Talks Drug Pricing Intiatives
Josh LaRosa, policy director at Wynne Health Group, in a new Relentless Health Value podcast highlights a number of drug [...]
Express Scripts Releases Annual Drug Trend Report
Express Scripts in its annual Drug Trend Report suggests drugs targeting inflammatory conditions were responsible for almost half of the [...]
COTA White Paper Spotlights Perspectives on RWE
A new white paper from COTA offers unique perspectives on real-world evidence (RWE), including input from Pfizer and Bristol-Myers Squibb [...]
Amyrt’s Myalept Tops Ranking of Pharmacy Drugs by Price
Amyrt Pharma's Myalept is the most expensive pharmacy drug at $71,306 per month, according to a GoodRx report which ranks [...]
ISPOR Launches International Search for New Editor-in-Chief of Value & Outcomes Spotlight Magazine
The International Society for Pharmacoeconomics and Outcomes Research (ISPOR) is launching an international search for a new editor-in-chief for its [...]
Lown Institute’s Saini, Brownlee Talk Shkreli Awards
Lown Institute's Vikas Saini, president, and Shannon Brownlee, senior vice president, discuss the latest Shkreli Awards winners on the Relentless [...]
Randomization vs. Real-World Evidence
Nonrandomized observational studies have been touted by some as being a viable alternative to randomized clinical trials, but are they [...]
Report Outlines How States Can Act on Drug Spending
A recent report by the Center for American Progress outlines how states can take action to reduce prescription drug spending. [...]
Massachusetts to Pay for Zolgensma on One Condition: It Must Work
Massachusetts' Medicaid program, MassHealth, has inked a conditional deal for Novartis' $2 million one-time spinal muscular atrophy (SMA) gene therapy, [...]
PRMA’s White Outlines Expanded U.S. Presence
PRMA Consulting's Nathan White, senior principal and U.S. practice lead, in a recent interview outlines the agency's latest expansion in [...]